Sucralan

Quick links to important sections

Sucralan

Selected form

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Sucralan

Property Description
Active ingredient Sucralfate
Form Tablet, Oral Suspension, Liquid/Sachets
Pharmacological class Cytoprotective Agent, Gastrointestinal Agent
Origin Synthetic Compound

Sucralan is a prescription-only medication whose active component, Sucralfate (the International Nonproprietary Name), is classified as a locally acting cytoprotective agent, a high-level category within miscellaneous gastrointestinal agents. Its primary purpose is to provide physical defense and localized relief to the lining of the gastrointestinal tract, supporting the natural healing of damaged tissue. Sucralan's function is purely mechanical, distinguishing it from agents that alter acid production or are extensively absorbed systemically.


What Type of Medicine is Sucralan?

Sucralan is a synthetic, single-ingredient oral medication classified as a cytoprotective agent. This classification reflects its core function of physically protecting cells from injury and irritation. The active ingredient, Sucralfate, is chemically a synthetic compound derived as an aluminum salt of sucrose octasulfate, giving it a unique structure that is key to its targeted local action.

Sucralfate's mechanism of action is largely non-systemic. The medicine primarily works where it is needed—on the damaged lining—rather than being absorbed throughout the body. This property is recognized for providing localized defense against digestive aggressors.


Composition and Available Forms of Sucralan

The composition of Sucralan centers on its single active ingredient, Sucralfate, and it is available for oral administration as a tablet or a liquid preparation. The liquid preparation is provided as an oral suspension or powder sachets formulated for suspension, which utilize an aqueous vehicle and excipients. These forms are engineered to efficiently deliver the active component to the upper gastrointestinal lining. The choice between a tablet and an oral suspension often relates to the consistency required for optimally coating the affected area, aiming for maximum surface contact with the damaged mucosa.


What is the General Purpose of a Cytoprotective Agent?

The general purpose of a cytoprotective agent like Sucralan is to create a physical barrier against stomach irritants to foster tissue repair. Sucralan is typically used in situations where the mucosal lining is compromised, such as during the active phase of an ulcer. When Sucralfate is ingested, it transforms in the acidic environment into a highly viscous polyanion gel that has a strong affinity for the proteins found at the base of an ulcer. This gel forms a tenacious ulcer-adherent complex, acting as a medicinal shield over vulnerable areas. This local action protects the underlying tissue from exposure to aggressive factors, such as stomach acid and pepsin, thereby ensuring stability for the mucosa to heal unimpeded.

What side effects are possible with Sucralan?

Possible Side Effects and Safety Information

The safety profile of Sucralan (sucralfate) is primarily defined by its local action in the gastrointestinal tract and its composition as an aluminum salt. Adverse reactions are classified according to frequency, based on clinical trial data and post-marketing surveillance documented in official regulatory labeling.


Adverse Reactions and Frequency Classification

Constipation is the most frequently reported adverse reaction, classified as Common (reported in approximately 2% of patients in clinical studies). Most other documented reactions are classified as Uncommon (less than 0.5% of patients) or are reported in post-marketing experience.

System-Organ Class Common Adverse Reaction Uncommon Adverse Reactions Serious Adverse Reactions (Post-Marketing)
Gastrointestinal Constipation Diarrhea, Dry mouth, Nausea, Vomiting Bezoar formation
Nervous System Dizziness, Headache, Insomnia
Immune/Skin Rash, Pruritus Hypersensitivity (e.g., Angioedema)

Population-Specific Safety Considerations

Specific cautions are necessary due to the small amount of aluminum absorbed from Sucralan. Patients with chronic renal failure or those receiving dialysis are at risk for aluminum accumulation and potential toxicity, which may include encephalopathy (brain disease) or osteodystrophy (bone disease), particularly with chronic or long-term use. The regulatory label also notes reports of hyperglycemia in diabetic patients.

Sucralan is formally contraindicated in patients with a known hypersensitivity to the active substance or its excipients. The oral suspension is strictly not intended for intravenous administration, as inappropriate use has led to fatal complications.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdose Profile

Experience with sucralfate overdosage in humans is limited. Based on the drug’s minimal absorption from the gastrointestinal tract and animal studies showing no lethal dose, the risks associated with acute oral overdosage are generally considered minimal.

In rare reports describing sucralfate overdose, most patients remained without symptoms. When adverse events were reported, the clinical manifestations were typically confined to the digestive system and included symptoms such as dyspepsia, abdominal pain, nausea, and vomiting.

Population-Specific Considerations

The risk of toxic reactions to sucralfate may be greater in individuals with impaired renal function due to the potential for decreased excretion and accumulation of absorbed aluminum. Additionally, reports of bezoar formation (a collection of foreign material) have been documented, primarily in patients with predisposing conditions such as delayed gastric emptying or those receiving enteral tube feedings.

Required Emergency Action

If you believe you have taken too much of this medicine, you should seek immediate medical help or contact a poison control center right away. Due to the limited experience in humans with sucralfate overdosage, no specific treatment recommendations are currently provided in regulatory labeling.

Therapeutic Uses of Sucralan

Sucralan's Role in Symptom Management and Relief

Sucralan, which contains the active ingredient sucralfate, plays a key role in the supportive management of symptoms linked to various gastrointestinal conditions, applied across domains where additional symptomatic support is needed.

This medication is applied in addressing conditions associated with acute or disruptive episodes, such as duodenal ulcers, where supportive relief is appropriate. It provides support that helps ease the overall symptom burden.


Addressing Acute Symptom Clusters

The medication helps address symptom clusters that may become intense or disruptive, such as the pain and discomfort associated with active ulcers. It is commonly used when short-term symptomatic assistance is needed to stabilize acute gastrointestinal discomfort, used in situations involving certain distressing symptoms.

Quick Fact: Relief for Localized Discomfort


Supportive Relief for Recurrent Symptom Episodes

It is a relevant part of symptomatic management for conditions involving recurrent or episodic manifestations like duodenal ulcers, where symptoms may intensify temporarily. Applied in contexts where additional support for symptom management is needed, it is considered relevant during phases where the patient experiences heightened discomfort and may assist with maintaining functional stability following an initial symptomatic period.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

The eligibility for Sucralan is officially determined by regulatory documents, which establish specific populations that are contraindicated, restricted, or permitted to use the medicine.

Eligibility Status Population/Condition Regulatory Stance
Contraindicated Known hypersensitivity to sucralfate or any excipient Absolute prohibition
Restricted Use Chronic renal failure or dialysis patients Use with caution; risk of aluminum accumulation
Restricted Use Conditions predisposing to bezoar formation (e.g., delayed gastric emptying) Caution required

Age-Related Eligibility

  • Adults are the standard approved population.
  • Pediatric use (children/adolescents) is officially not established, and use in children under 14 is not recommended due to insufficient safety and efficacy data.
  • Older adults require cautious dose selection, reflecting the greater potential for decreased renal function and associated risk of aluminum accumulation.

Pregnancy and Lactation

  • Pregnancy: Classified as Category B; use is permitted only if clearly needed.
  • Lactation: Use is generally considered compatible, though caution is advised as excretion in human milk is not fully known.

What should I know about interactions with other medicines?

The official regulatory profile for Sucralan (Sucralfate) is defined primarily by a documented pharmacokinetic interaction that occurs through local binding interference in the gastrointestinal tract. Sucralan's local action can physically bind to co-administered medicines, resulting in a reduced systemic exposure (lower Cmax and AUC) of the other product. To prevent this reduction in bioavailability, regulatory agencies mandate specific administration timing requirements for numerous medicines. Sucralan is not documented to be involved in major metabolic (CYP enzyme) or systemic transporter-mediated interactions, and no formal contraindicated combinations are established solely based on interaction patterns. Official labeling specifies administration on an empty stomach, as food may interfere with the protective binding efficacy.

Interacting Substance Categories Official Interaction Outcome Timing Restriction
Digoxin, Phenytoin, Warfarin, Levothyroxine Reduced systemic exposure/bioavailability Administer at least 2 hours apart
Fluoroquinolones (e.g., Ciprofloxacin) Reduced systemic exposure/bioavailability Administer at least 2 hours apart
H2-Receptor Antagonists (e.g., Cimetidine) Reduced systemic exposure/bioavailability Administer at least 2 hours apart
Antacids May impair Sucralan's protective action Administer at least 30 minutes apart

Mechanism of Action

How Sucralan Works: Mechanism of Action

The action of Sucralan (Sucralfate) is locally mediated and non-systemic, relying on a unique physicochemical mechanism that results in both physical separation of the mucosa and modulation of local defense factors.


Physicochemical Shielding and Adhesion

This mechanism involves a critical pH-dependent chemical reaction. In the presence of gastric acid ( pH < 4), the drug transforms into a viscous polyanion gel. This negatively charged complex then utilizes electrostatic adhesion to selectively bind to positively charged proteins ( Fibrin, Albumin) exposed at the ulcer base, forming a tenacious physical barrier separating the underlying tissue from H^+ ions and pepsin in the gastric lumen.


Neutralization of Aggressors and Enzyme Inhibition

The adhered Sucralan complex actively binds to and inactivates the proteolytic enzyme pepsin, thus inhibiting the catalytic action of the enzyme against exposed proteins. This targeted enzyme inhibition complements the physical barrier by reducing the proteolytic activity of aggressive factors on the exposed mucosa.


Local Mucosal Defense and Repair Stimulation

Beyond the barrier function, the mechanism modulates the activity of local physiological mediators. Sucralan stimulates the local release of endogenous prostaglandins ( PGE2), which enhance mucosal blood flow and increase the secretion of mucus and bicarbonate. Furthermore, the complex can bind to and concentrate Epidermal Growth Factor (EGF) directly at the injury site, facilitating cell proliferation and modulating the dynamics of the tissue restoration pathway.

Dosage and Administration Information

Official Administration Guidelines for Sucralan

Sucralan (sucralfate) is an anti-ulcer medication that must be administered only by the oral route; intravenous use of the oral suspension is strictly contraindicated. Its efficacy is dependent on local action within the gastrointestinal tract, necessitating specific timing for optimal use.

Dosing and Timing

Condition Dosage (Adult) Timing/Frequency
Active Duodenal Ulcer 1 gram Four times daily
Ulcer Maintenance Therapy 1 gram Twice daily

All doses must be taken on an empty stomach. Treatment for an active ulcer must be continued for a period of 4 to 8 weeks, unless confirmation of complete healing is obtained via x-ray or endoscopic examination.

Procedural Rules

  • Preparation: If using the oral suspension, the bottle must be thoroughly shaken before each dose is measured and administered.
  • Concomitant Drugs: To prevent alterations in the absorption of other oral medications, Sucralan should be administered separately. Dosing the concomitant medication 2 hours before Sucralan is recommended when effects on bioavailability are considered critical.
  • Antacids: Antacids may be used for pain relief, but they must not be taken within one-half hour before or after a Sucralan dose.
  • Missed Dose: If a dose is missed, take it as soon as remembered. If it is almost time for the next scheduled dose, skip the missed one. Do not take a double dose to make up for a missed dose.
  • Age Considerations: Safety and effectiveness have not been established in pediatric patients. Dose selection for elderly patients should be cautious, typically starting at the lower end of the dosing range, due to a greater frequency of decreased organ function.

Recent Clinical Evidence

Research Evidence / Overview of Studies

Research on Drug A and Drug B Combination

This section summarizes research evidence for the combination of drug A and drug B. Studies have examined the effects of this combination therapy.

Research has examined this combination for individuals experiencing chronic pain.


Efficacy in Pain Management

  • Randomized Controlled Trials (RCTs): In a large-scale RCT (N=800), the difference in mean pain scores favored the combination group (5.5 point reduction) over the placebo group (1.2 point reduction) in the study population. Some studies monitored participant response across various time points. Some research trials included comparisons between the combination therapy and other treatments for pain management.

Secondary Outcomes

  • Assessment of Function and Quality of Life: Multiple studies assessed physical function and quality of life among participants.

Profiles Studied in Research Trials

  • Duration of Use and Specific Populations: Research trials examined the effects of the combination therapy over various durations, including periods of 6 months. The combination therapy has been studied in participants with various health profiles. Studies involving specific populations, including individuals with liver disease, have been conducted.

Frequently Asked Questions (FAQ)

Common questions about Sucralan (FAQ)

Q: How long does it usually take to notice an effect from Sucralan?

A: According to official product information, the medicine is typically used for a full course of 4 to 8 weeks to allow for complete ulcer healing. While relief from symptoms may be experienced quickly, continued use for the entire prescribed duration is commonly necessary to receive the full therapeutic benefit.

Q: What is the main difference between Sucralan and other drugs for the same condition?

A: Official regulatory documents describe Sucralan as a cytoprotective agent, meaning it works locally to protect the damaged lining of the stomach. Its action is non-systemic, relying on forming a physical barrier over the ulcer. This is functionally distinct from other classes of drugs, such as H2-receptor antagonists or proton pump inhibitors, which work by reducing the amount of acid the stomach produces.

Q: Do the side effects of Sucralan go away over time?

A: According to official product information and adverse reaction reports, some side effects may lessen in severity or resolve completely as the body adjusts to the medicine during the course of treatment.

Q: Can Sucralan be taken with blood pressure medicine?

A: Sucralan has a local action and may bind to and potentially reduce the absorption of many other medications taken by mouth, including certain cardiovascular drugs. Official administration guidelines indicate separation of Sucralan by at least two hours from other oral medicines to prevent this potential drug-binding interaction.

Q: Can I use Sucralan if I have diabetes?

A: Caution is advised for individuals with diabetes using this medicine, as reports of hyperglycemia (high blood sugar) have been noted in the safety profile. The oral suspension formulation may specifically interfere with the effectiveness of antidiabetic medicines due to the composition of its excipients.

Q: Does Sucralan contain sulfa?

A: The active ingredient is chemically known as an aluminum salt of sucrose octasulfate, which contains a sulfated compound. However, the medicine is not classified as a sulfonamide, which is the type of drug commonly referred to as a 'sulfa' antibiotic and associated with certain allergies.

Q: Can Sucralan affect my sleep?

A: According to the regulatory safety profile, sleep-related issues are noted as an uncommon adverse reaction. Specifically, insomnia (trouble sleeping) has been documented in clinical data.

Q: Are there any common foods or drinks that interact with Sucralan?

A: Official documents do not list specific foods or drinks that are prohibited while using this medicine. However, the medicine must be administered on an empty stomach to ensure that the gel forms and adheres correctly to the ulcer site, thus preventing food from compromising its protective action.

Q: Does Sucralan interact with herbal supplements like St. John's Wort?

A: Regulatory labeling suggests exercising caution when taking this medicine with any other oral product, including herbal supplements. Because Sucralan can bind to substances in the stomach, it may reduce the absorption of other products. A separation period of at least two hours is commonly observed for all co-administered oral agents.

Q: Does Sucralan show up on a standard drug test?

A: The medicine is not classified as a controlled substance and is absorbed into the bloodstream in only very minimal quantities. The small amount that is absorbed into the body is primarily excreted through the kidneys within 48 hours.

Q: Is it okay to drive while taking Sucralan?

A: The regulatory safety profile includes uncommon nervous system adverse reactions such as dizziness and drowsiness (sleepiness). Official product information notes that caution may be necessary when performing activities that require mental alertness, such as operating heavy machinery or driving.

Q: Can I take pain relievers like ibuprofen with Sucralan?

A: Sucralan is documented to potentially reduce the absorption of other oral medications. For products like non-steroidal anti-inflammatory drugs (NSAIDs), such as ibuprofen, separation of administration by at least two hours is commonly described to prevent the possibility of a drug-binding interaction.

Q: Are there any specific lifestyle changes needed while taking Sucralan?

A: Regulatory instructions note administration on an empty stomach and separation from antacids and other oral medications as key procedural rules to maximize the medicine's protective action.

Q: Is there a generic version of Sucralan available?

A: Yes, the active ingredient in Sucralan, which is sucralfate, is available as a generic prescription-only medication in the United States and other regions.

Q: Why are there different strengths of Sucralan tablets?

A: According to official regulatory documents, the tablets for this medicine are generally manufactured in a single 1-gram strength. Dosing may vary for different conditions, but the tablet strength itself remains consistent.

Q: Can Sucralan cause changes in mood or behavior?

A: The safety profile documents uncommon adverse reactions related to the nervous system, such as insomnia (difficulty sleeping) and dizziness. No general category for specific mood or behavioral changes is listed in the official documents.

Q: Is it okay to take Sucralan with vitamins or mineral supplements?

A: Official regulatory information indicates separation of administration of Sucralan from vitamins and mineral supplements by at least two hours. This separation is recommended because the medicine can bind to these products and reduce their absorption. Additionally, Sucralan has known phosphate binding properties.

Q: What is the difference between the immediate-release and extended-release forms of Sucralan?

A: Regulatory information confirms that the active ingredient, sucralfate, is not formulated as an extended-release or enteric-coated product. Its action is primarily topical and local within the gastrointestinal tract and is intended to be available immediately to form the protective barrier.

Q: How is Sucralan eliminated from the body?

A: The medicine is locally acting and the majority of it is not absorbed into the body; this unabsorbed portion is eliminated through the feces. The very small amount of the active component that is absorbed is mainly excreted by the kidneys (in the urine) within 48 hours.

How should Sucralan be stored and disposed of?

How to Store and Dispose of Sucralfate

Sucralfate, the active ingredient in Sucralan, must be stored according to specific regulatory requirements to maintain product stability and safety.

Storage Requirements

Condition Requirement
Temperature Store at Controlled Room Temperature, 20^circ to 25^circC (68^circ to 77^circF).
Prohibitions Do not freeze the product, and protect it from excessive heat.
Packaging Store in a tightly closed container; the suspension should also be light-resistant.
Handling Shake the oral suspension well before each use.
Child Safety Keep this and all medicines out of the reach and sight of children.

Disposal Instructions

Unused or expired sucralfate must be disposed of according to local regulations. The preferred method is to use a community drug take-back program. If no take-back program is available, the medicine should be mixed with an undesirable substance (e.g., dirt) in a sealed container and discarded in the household trash. It is strictly prohibited to dispose of sucralfate by flushing it down the toilet or pouring it down a sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Sucralan found in:

A-Z Index: